START has appointed Salwan Al Mutar as director of clinical research in Dallas-Fort Worth, strengthening its early-phase oncology capabilities in North Texas.

The move appears to be a mix of genuine leadership news and corporate positioning, with clear emphasis on expanding access to trials and reinforcing START’s market presence in a high-growth region.

Al Mutar joins the network with experience in gastrointestinal oncology and early-phase clinical trials, where he has worked across Phase 1 to Phase 3 studies, including first-in-human and combination therapies. His background includes roles in academic medicine and clinical research, with a focus on pancreatic cancer and biomarker-driven treatments.

At START, he will oversee clinical research operations and support the growth of early-phase oncology programmes in the Dallas-Fort Worth area. He will work alongside principal investigator Henry Xiong and an established research team managing trial delivery at the site.

Nick Slack, chairman and CEO at START, said: “START is built to accelerate oncology drug development where it matters most—at the point of care in the community. Dr Al Mutar brings deep disease expertise and clinical trial leadership across a variety of oncology indications.”

Slack added that the appointment strengthens the organisation’s ability to run complex early-phase studies while expanding patient access to investigational therapies in the region.

The Dallas-Fort Worth area represents a significant opportunity for oncology research, with around 40,000 new cancer cases diagnosed annually. START’s presence in the region is supported through partnerships with OneOncology and The Center for Cancer and Blood Disorders, enabling access to a broad patient population and referral network.

The site is designed to support early-phase trials through dedicated infrastructure and operational teams, with a focus on study start-up timelines and patient enrolment.

Al Mutar said: “Patients with aggressive and advanced cancers often face limited options, and clinical trials can represent a critical path forward. What drew me to START is the ability to bring those options closer to where patients already receive care, without compromising on scientific rigor or trial complexity.”

His comments reflect a broader industry shift towards decentralising early-phase trials and embedding research within community oncology settings, rather than relying solely on large academic centres.

Chris Takimoto, chief medical officer at START, said: “His expertise in gastrointestinal malignancies and biomarker-driven development strengthens our ability to support sponsors with complex early-phase programs, while continuing to expand access for patients who may benefit from innovative therapies.”

START operates a global network of clinical trial sites focused on early-stage oncology research and has conducted more than 1,000 early-phase trials. The organisation reports involvement in the development of more than 50 therapies that have received regulatory approval.

The appointment of Al Mutar signals continued investment in regional clinical trial infrastructure, as competition grows to recruit patients and deliver early-phase oncology studies more efficiently.